Celgene acquisition stock price
CELG: Get the latest Celgene stock price and detailed information including CELG news, historical charts and realtime prices. The company's stock sank when the acquisition was first announced, and dropped again when Bristol-Myers announced it would be selling Celgene's Otezla. Now that the dust has settled, though, those Celgene Corporation (NASDAQ: CELG) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Bristol-Myers Squibb agreed to acquire Celgene for about $74 billion, creating a cancer-drug powerhouse, but one with questions about its long-term prospects.
Celgene shareholders will receive one Bristol-Myers share and $50.00 in cash for each share of Celgene. The cash-and-stock value of the deal is $102.43 per share and represents a premium of about 54% to Celgene’s Wednesday closing price of $66.64.
That values Celgene stock at $102.43 per share based on the closing price of BMS on Jan. 2, 2019. The main reason why this is a bad deal for Celgene is that the biotech is simply worth more than that. The proposed price tag translates to Celgene trading at less than 10 times expected earnings. Bristol-Myers Squibb - Get Report shares edged higher Thursday after the pharmaceutical group said it has completed its $74 billion acquisition of cancer drug specialist Celgene Corp. - Get Report. Celgene Corp. made a big splash in the acquisition arena when it announced it would purchase Impact Biomedicines, a privately held company, for up to $7 billion should specific milestones be met Under the terms of the merger, Celgene shareholders received for each share, 1.00 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved. Under the agreement, Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of 53.7 percent to Celgene’s Wednesday close. Shares of Celgene surged 28 percent in midmorning trading, to near $85 per share, Get breaking news and analysis on Celgene Corporation (CELG) stock, price quote and chart, trading and investing tools. Bristol-Myers Gets FTC Clearance for Celgene Acquisition. at Zacks.com
19 Mar 2019 The board of the two firms welcome the acquisition which will imply that Bristol- Myers Celgene stock price decline on drug's sluggish sales.
The company's stock sank when the acquisition was first announced, and dropped again when Bristol-Myers announced it would be selling Celgene's Otezla. Now that the dust has settled, though, those
Now that Bristol has officially acquired Celgene, is it time to buy BMY stock? 20. GAMCO Investors
3 Jan 2019 Bristol Myers-Squibb is acquiring Celgene in a cash and stock deal valued at As the price of long-term Bristol bonds fell, the associated credit Why is the CVR trading for a price different than the potential $9.00 payout? Myers Squibb stock, $50 cash and 1 CVR for each of my vested Celgene shares )?. Now that Bristol has officially acquired Celgene, is it time to buy BMY stock? 20. GAMCO Investors 20 Nov 2019 Celgene common stock ceased trading as of the close of trading today. Stock Exchange, with the CVRs trading under the symbol “BMYRT.”. 20 Nov 2019 Bristol-Myers Squibb completes $74 billion acquisition of Celgene The FTC required Bristol-Myers and Celgene sell the rights to Otezla, Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq 22 Nov 2019 Catching Up With Bristol-Myers Stock After Celgene Acquisition Thursday, near their closing price the day before despite heavy volume.
3 Jan 2019 Key Points Investors have turned a thumbs down on the proposed acquisition of Celgene resulting in a 14% plunge in the stock price of BMY to
Get breaking news and analysis on Celgene Corporation (CELG) stock, price quote and chart, trading and investing tools. Bristol-Myers Gets FTC Clearance for Celgene Acquisition. at Zacks.com
12 brokers have issued 1 year target prices for Celgene's stock. Their forecasts range from $94.00 to $115.00. On average, they expect Celgene's share price to reach $102.26 in the next year. This suggests that the stock has a possible downside of 5.5%. View Analyst Price Targets for Celgene. Now that the controversial acquisition of biotech giant Celgene (ticker: CELG) by pharmaceutical giant Bristol-Myers Squibb (BMY) for around $74 billion seems all but a done deal, analysts are taking a hard look at the nascent Frankenstein’s monster of a drug company—and throwing their hands in the air. Based on the closing price of Bristol-Myers Squibb stock on January 2, 2019, the cash and stock consideration to be received by Celgene shareholders is valued at $102.43 per share. Each Celgene share you hold will be exchanged for: 1 share of Bristol Myers Squibb common stock (NYSE: BMY) $50 cash; 1 CVR (NYSE: BMYRT)